Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 30, 2015 8:16 PM ET


Company Overview of Applied Genetic Technologies Corporation

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products to treat patients with severe inherited orphan diseases in ophthalmology in the United States. The company’s lead product candidates include treatments for X-linked retinoschisis, achromatopsia, and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye caused by mutations in single genes. It is also developing adeno-associated virus based gene therapies for the treatment of rare eye diseases; and a product candidate for treatment of alpha-1 antitrypsin deficiency for which it has conducted preclinical proof-of-concept studies and Phase I and Phase II clinic...

11801 Research Drive

Suite D

Alachua, FL 32615

United States

Founded in 1999

35 Employees



Key Executives for Applied Genetic Technologies Corporation

Chief Executive Officer, President and Director
Age: 54
Total Annual Compensation: $400.0K
Chief Financial Officer
Age: 59
Total Annual Compensation: $300.0K
Chief Medical Officer and Vice President
Age: 68
Total Annual Compensation: $350.0K
Chief Business Officer and Vice President
Age: 59
Total Annual Compensation: $127.1K
Executive Director of Process Development
Age: 42
Total Annual Compensation: $122.4K
Compensation as of Fiscal Year 2015.

Applied Genetic Technologies Corporation Key Developments

Applied Genetic Technologies Corporation Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat Achromatopsia

Applied Genetic Technologies Corporation announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its gene therapy product candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene. The company presented early preclinical findings in a naturally occurring dog model of the CNGB3 form of the disease, and previously received orphan drug designation from the FDA and the EMA for its investigational gene therapy product for the treatment of an additional variant of achromatopsia caused by mutations in the CNGB3 gene. More recent studies conducted by company's collaborators showed that in sheep affected by achromatopsia caused by mutations in the CNGA3 gene, delivery of an AAV vector carrying a normal copy of CNGA3 restored vision, as measured by the ability to navigate an obstacle maze. Orphan drug designation, covered by the U.S. Orphan Drug Act of 1983, is granted to drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 individuals. Products receiving orphan drug designation are eligible to receive market exclusivity for a period of seven years, an accelerated regulatory review process, an exemption from certain taxes and user fees and additional clinical support from FDA.

Applied Genetic Technologies Corporation Presents at Credit Suisse 24th Annual Healthcare Conference, Nov-11-2015 10:00 AM

Applied Genetic Technologies Corporation Presents at Credit Suisse 24th Annual Healthcare Conference, Nov-11-2015 10:00 AM. Venue: The Phoenician Hotel, Scottsdale, Arizona, United States. Speakers: Lawrence E. Bullock, Chief Financial Officer.

Applied Genetic Technologies Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2015

Applied Genetic Technologies Corporation reported unaudited consolidated earnings results for the first quarter ended September 30, 2015. Total revenue for the three months ended September 30, 2015 was $11.1 million compared to $705,000 generated during the same period in 2014. The increase was largely attributable to the recognition as revenue of a portion of the nonrefundable upfront fees received in August 2015 by the company under its collaboration agreement with Biogen, and milestone revenue of $5.0 million that was recorded during the quarter following achievement of a patient enrollment-based milestone under that collaboration. For the three months ended September 30, 2015, the company incurred a net loss of $9.1 million, up from a loss of $5.4 million during the same period in 2014. Loss from operations was $9,213,000 against $5,381,000 a year ago. Net loss per share, basic and diluted was $0.53 against $0.34 a year ago.

Similar Private Companies By Industry

Company Name Region
Immunotherapy Worldwide United States
Synthrx, Inc. United States
Maxygen, Inc. United States
Dilyx Biotechnologies, LLC United States
AzurRx BioPharma, Inc. United States

Recent Private Companies Transactions

Private Placement
July 2, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Applied Genetic Technologies Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at